Tvardi Therapeutics Reports Positive Phase 1 Results for TTI-109, Shares Surge
Tvardi Therapeutics' stock price rises significantly after the company announces positive Phase 1 results for its next-generation STAT3 inhibitor, TTI-109.
Editorial Staff 6 days ago